Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes


Manage episode 287027739 series 9912
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts are continuing to refine and expand the role of immunotherapies in SCLC. To make the most of this novel therapeutic approach, it is essential for oncology professionals as well as the broader multidisciplinary team of professionals to keep up with the latest therapeutic advances and collaborate effectively to establish the diagnosis, ensure a rapid initiation of therapy, and appropriately manage potential immune-related adverse events. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. Leading experts provide an engaging educational session on the latest science, best practices, and multidisciplinary implications related to integrating cancer immunotherapies into the management plans for patients with ES-SCLC. Upon completion of this activity, participants will be able to: Describe the epidemiology, clinical features, and current treatment of extensive-stage small cell lung cancer (ES-SCLC), including immunotherapies that can improve long-term outcomes, Examine the latest efficacy, safety, and biomarker data from clinical trials evaluating available and emerging immunotherapies and immune-based combinations for ES-SCLC, Implement optimal strategies for screening, diagnosing, and staging of patients with lung cancer to ensure timely and accurate diagnosis, prompt oncology referral, and rapid treatment initiation for patients with ES-SCLC, Apply best practices for collaboration and coordination of care with oncologists and other members of the multidisciplinary lung cancer team to provide optimal care to patients with ES-SCLC, including the integration of immunotherapies into treatment plans and recognition/management of irAEs, and improve outcomes.

449 つのエピソード